Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.47 |
| ▸ | JAK3 | P52333 | 9/20 | 0.47 |
| ▸ | JAK1 | P23458 | 7/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2377450 | 0.94 | JAK2 (0.48) | JAK2JAK3JAK1MAPK1USP30 | |
| Ethylenediamine SCHEMBL2377655 | 0.92 | JAK2 (0.46) | JAK2JAK3JAK1MAPK1USP30 | |
| SCHEMBL2378493 | 0.92 | JAK2 (0.46) | JAK2JAK3JAK1MAPK1USP30 | |
| SCHEMBL2378776 | 0.92 | JAK2 (0.48) | JAK2JAK3JAK1MAPK1 | |
| SCHEMBL2376949 | 0.92 | JAK2 (0.57) | JAK2JAK3JAK1MAPK1 | |
| SCHEMBL2376961 | 0.92 | JAK2 (0.57) | JAK2JAK3JAK1MAPK1 | |
| SCHEMBL2378351 | 0.92 | JAK2 (0.57) | JAK2JAK3JAK1MAPK1 | |
| SCHEMBL2376098 | 0.91 | JAK2 (0.46) | JAK2JAK3JAK1MAPK1USP30 | |
| SCHEMBL2378372 | 0.91 | JAK2 (0.46) | JAK2JAK3JAK1MAPK1USP30 | |
| SCHEMBL2379250 | 0.91 | JAK2 (0.46) | JAK2JAK3JAK1MAPK1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373653-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010063634-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | JAK2 5/4885JAK3 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.